Live corpus
Active intelligence prompt Pediatric cancer: surface high-value therapeutic signals across pediatric oncology literature.
PEDIATRIC CANCER RESEARCH INTELLIGENCE

Finding therapies hidden in 37,031 pediatric cancer papers.

Neurocompute scores pediatric oncology literature, surfaces overlooked therapeutic signals, and turns fragmented childhood cancer research into a living discovery terminal.

37,031 Papers indexed
371 Papers AI scored
37,031 Ranked papers
100.0% Coverage
PATIENT-FRIENDLY SUMMARY

CHIP-AML22: a complex clinical trial in de novo pediatric AML patients, including a gemtuzumab ozogamicin randomization and targeted therapy with quizartinib in eligible subgroups, within the NOPHO-DB-SHIP consortium.

For education only—not personal medical advice.

LIVE PEDIATRIC ONCOLOGY INTELLIGENCE
↑ Therapeutic signals emerging ↑ New pediatric cancer papers ingested ↑ Cross-paper convergence detected ↑ Human relevance scores updating ↑ Overlooked treatment paths surfacing
TOP PEDIATRIC CANCER SIGNALS

Ranked Discovery Journal Articles

View all discoveries →
LATEST PEDIATRIC CANCER PAPERS

Database feed

Last ingest 2026-08-17 09:15 AM
PEDIATRIC CANCER RESEARCH TERMINAL

All ranked pediatric cancer papers

37031 results
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 79.7/100. Study design: 100.0; human relevance: 100.0; therapeutic relevance: 26.2; sample size: 60.0; recency: 100.0; abstract quality: 85.0.

B
Inflammatory markers and self-regulation improvements in children and adolescents with obesity during inpatient treatment.
PMID 41082951 Published: 2025-10-11 Ingested: 2026-08-02 12:05 AM Brain, behavior, and immunity
AI -
Base 79.74
Rank 79.74
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 79.7/100. Study design: 100.0; human relevance: 100.0; therapeutic relevance: 26.2; sample size: 60.0; recency: 100.0; abstract quality: 85.0.

B
The impact of in utero exposure to cancer treatments on foetal reproductive development and future fertility: a systematic review.
PMID 40843459 Published: 2025-07-23 Ingested: 2026-08-02 12:03 AM Human reproduction open
AI -
Base 79.74
Rank 79.74
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 79.7/100. Study design: 95.0; human relevance: 75.0; therapeutic relevance: 56.2; sample size: 60.0; recency: 90.0; abstract quality: 100.0.

B
AI -
Base 79.74
Rank 79.74
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 79.7/100. Study design: 95.0; human relevance: 75.0; therapeutic relevance: 66.2; sample size: 40.0; recency: 90.0; abstract quality: 100.0.

B
AI -
Base 79.72
Rank 79.72
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 79.7/100. Study design: 95.0; human relevance: 75.0; therapeutic relevance: 58.6; sample size: 60.0; recency: 100.0; abstract quality: 85.0.

B
AI -
Base 79.7
Rank 79.7
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 79.7/100. Study design: 95.0; human relevance: 75.0; therapeutic relevance: 51.0; sample size: 60.0; recency: 100.0; abstract quality: 100.0.

B
Anlotinib plus toripalimab in patients with advanced bone and soft tissue sarcomas including ultra-rare sarcomas: A multicenter, single-arm, phase 2 trial.
PMID 42258994 Published: 2026-06-06 Ingested: 2026-08-02 12:07 AM European journal of cancer (Oxford, England : 1990)
AI -
Base 79.7
Rank 79.7
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 79.7/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 51.0; sample size: 40.0; recency: 100.0; abstract quality: 85.0.

AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 79.7/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 23.5; sample size: 80.0; recency: 100.0; abstract quality: 100.0.

B
Effects of PM2.5 Reduction Interventions on Cardiovascular Indicators: A Meta-analysis.
PMID 41057567 Published: 2025-10-07 Ingested: 2026-08-02 12:05 AM Cardiovascular toxicology
AI -
Base 79.7
Rank 79.7
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 79.7/100. Study design: 100.0; human relevance: 75.0; therapeutic relevance: 28.5; sample size: 90.0; recency: 100.0; abstract quality: 100.0.

AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 79.7/100. Study design: 80.0; human relevance: 95.0; therapeutic relevance: 53.5; sample size: 60.0; recency: 100.0; abstract quality: 100.0.

B
Population Pharmacokinetics Modeling of Selpercatinib to Support Posology in Pediatric Patients With RET-Altered Metastatic Thyroid Cancer or Solid Tumors.
PMID 40358020 Published: 2025-05-13 Ingested: 2026-08-02 12:12 AM CPT: pharmacometrics & systems pharmacology
AI -
Base 79.7
Rank 79.7
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 79.7/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 36.0; sample size: 80.0; recency: 90.0; abstract quality: 85.0.

Previous
Page 150 of 3086
Next
Pediatric cancer research intelligence graphic
PEDIATRIC CANCER VISUAL SYSTEM

Open the Research Intelligence Map

Explore the active pediatric oncology analysis view.

Expand Intelligence View →
Full Pediatric cancer research intelligence graphic